The High Authority of Health (HAS) recommended, Monday, February 21, to reserve vaccination with the Janssen vaccine for certain cases at risk of severe forms of Covid-19 pending the conclusions of the European Medicines Agency (EMA).
According to the HAS, the preliminary results of a study suggest a slight increase in the risk of myocardial infarction in the two weeks following the injection of the Janssen vaccine in adults under 75 years of age.
The independent public authority recalls, however, that these are preliminary data and that they must be confirmed by other studies at the international level, in particular a review of the MEA.
Postponing planned injections with the Janssen vaccine
The HAS thus recommends, pending the conclusions of the EMA, to postpone the injections planned with the Janssen vaccine, except in people at risk of a severe form of the disease who have a contraindication to messenger RNA vaccines ( mRNA).
HAS specifies, in accordance with the opinions it has already issued, that preference should be given to the use of mRNA vaccines for the first dose as well as for the booster dose when possible, including for people who have already received a dose of the Janssen vaccine as a first injection, because of their better efficacy.